U.S. indices bounced off Monday morning’s lows as investors weigh weak China retail and production data. Uncertainty around the COVID-19 Delta variant is also weighing on the market.
Moderna Inc (NASDAQ: MRNA) announced a double dose of positive tidings Monday, but the stock is still wallowing in the red amid a sell-off seen across vaccine stocks.
When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.
For 2022 and 2023, agreement provides for 20 million doses each year with option for additional 15 million doses each year
For 2024, agreement provides option for up to 35 million additional doses
Moderna,
Biopharma stocks retreated in the week ending Aug. 13, defying the optimism that was found in the broader market. Earnings continued to dominate the headlines, with small- and mid-cap companies among those reporting during the week.
The CNBC investor panel on Friday discussed NVIDIA Corp (NASDAQ: NVDA) ahead of its upcoming earnings report.
Nvidia is the "gold standard" in the semiconductor space, Odyssey Capital Advisors' Jason Snipe said.
This weekend's Barron's cover story takes a close look at what it will take to fix Boeing.
Other featured articles discuss reliable growth stocks, whether inflation is different this time and who has the early lead in the metaverse.